0.00
100.00%
-16.70
Orchard Therapeutics plc ADR stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $16.68 pivot point. If it approaches the $16.56 support level, significant changes may occur.
Previous Close:
$16.70
Open:
$0
24h Volume:
0
Market Cap:
$380.11M
Revenue:
$21.84M
Net Income/Loss:
$-72.92M
P/E Ratio:
0.00
EPS:
-6.2
Net Cash Flow:
$-94.41M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Orchard Therapeutics plc ADR Stock (ORTX) Company Profile
Name
Orchard Therapeutics plc ADR
Sector
Industry
Phone
44 20 3 808 8286
Address
108 Cannon Street, London
Orchard Therapeutics plc ADR Stock (ORTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-29-21 | Resumed | Cantor Fitzgerald | Overweight |
Nov-16-21 | Downgrade | JP Morgan | Neutral → Underweight |
Aug-18-21 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-02-21 | Resumed | JP Morgan | Overweight |
Mar-02-21 | Initiated | Stifel | Buy |
Jan-07-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
Sep-17-19 | Initiated | Guggenheim | Buy |
Sep-05-19 | Initiated | Barclays | Overweight |
Dec-17-18 | Upgrade | Goldman | Neutral → Buy |
Nov-26-18 | Initiated | Goldman | Neutral |
Nov-26-18 | Initiated | JP Morgan | Overweight |
Nov-26-18 | Initiated | Wedbush | Outperform |
View All
Orchard Therapeutics plc ADR Stock (ORTX) Latest News
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
GlobeNewswire Inc.
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
GlobeNewswire Inc.
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
GlobeNewswire Inc.
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
GlobeNewswire Inc.
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
Zacks Investment Research
Orchard Therapeutics plc ADR Stock (ORTX) Financials Data
Orchard Therapeutics plc ADR (ORTX) Revenue 2024
ORTX reported a revenue (TTM) of $21.84 million for the quarter ending September 30, 2023, a +35.21% rise year-over-year.
Orchard Therapeutics plc ADR (ORTX) Net Income 2024
ORTX net income (TTM) was -$72.92 million for the quarter ending September 30, 2023, a +59.29% increase year-over-year.
Orchard Therapeutics plc ADR (ORTX) Cash Flow 2024
ORTX recorded a free cash flow (TTM) of -$94.41 million for the quarter ending September 30, 2023, a +8.98% increase year-over-year.
Orchard Therapeutics plc ADR (ORTX) Earnings per Share 2024
ORTX earnings per share (TTM) was -$4.00 for the quarter ending September 30, 2023, a +71.63% growth year-over-year.
About Orchard Therapeutics plc ADR
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Cap:
|
Volume (24h):